Brain+ Valuation Multiples

Discover revenue and EBITDA valuation multiples for Brain+ and similar public comparables like Clarent, Omni Health, FOXO Technologies, Premier Health Of America and more.

Brain+ Overview

About Brain+

Brain+ AS is a digital therapeutics company. It is focused on developing and commercializing solutions for dementia care and with a primary focus on Cognitive Stimulation Therapy (CST). The company has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI). The company is developing Ayla, a scalable dementia care platform that provides software-based therapy and care solutions designed to support individuals with dementia.


Founded

2012

HQ

Denmark

Employees

12

Financials (FY)

Revenue: -
Net Income: -

Market Cap

$461K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Brain+ Stock Performance

Brain+ has current market cap of $461K.

Market Cap Evolution

Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$461K-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Brain+ Valuation Multiples

Brain+ Financial Valuation Multiples

As of September 2, 2026, Brain+ has market cap of $461K.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Brain+ Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Clarent0.0x-(0.0x)-
Omni Health1.4x-(0.6x)-
FOXO Technologies1.3x-(2.4x)-
Premier Health Of America0.4x0.4x(11.4x)-
MyndTec4.5x-(0.4x)-
VSee Health0.2x0.2x(0.3x)(1.0x)
Allurion1.7x1.8x(0.9x)-
Delic Hldgs0.0x-(0.0x)-

This data is available for Pro users. Sign up to see all Brain+ competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Brain+

When was Brain+ founded?Brain+ was founded in 2012.
Where is Brain+ headquartered?Brain+ is headquartered in Denmark.
How many employees does Brain+ have?As of today, Brain+ has over 12 employees.
Is Brain+ publicly listed?Yes, Brain+ is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of Brain+?Brain+ trades under BRAINP ticker.
When did Brain+ go public?Brain+ went public in 2021.
Who are competitors of Brain+?Brain+ main competitors include Clarent, Omni Health, FOXO Technologies, Premier Health Of America, MyndTec, VSee Health, Allurion, Delic Hldgs, Gelesis Hldgs, Binovi Technologies.
What is the current market cap of Brain+?Brain+'s current market cap is $461K.
Is Brain+ profitable?No, Brain+ is not profitable.
How many companies Brain+ has acquired to date?Brain+ hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Brain+ has invested to date?Brain+ hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Brain+

Lists including Brain+

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial